Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 47

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016', provides in depth analysis on Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview 7
Therapeutics Development 8
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Stage of Development 8
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Therapy Area 9
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Indication 10
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Products Glance 11
Early Stage Products 11
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Companies 12
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Universities/Institutes 14
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development 21
Alchemia Limited 21
AstraZeneca Plc 22
Carmot Therapeutics Inc 23
Diabetica Limited 24
Eli Lilly and Company 25
Longevity Biotech, Inc 26
Sanofi 27
Zealand Pharma A/S 28
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles 29
AC-163794 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
DAJC-1 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LBT-6030 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SAR-438335 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes and Obesity - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Synthetic Peptide to Agonize GLP-1 Receptor and GIP Receptor for Diabetes - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptides to Agonize GLP-1, GIP and Glucagon Receptors for Diabetes and Obesity - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ZPDI-70 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ZPI-98 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Projects 42
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products 43
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Featured News & Press Releases 44
Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting 44
Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Alchemia Limited, H2 2016 21
Pipeline by AstraZeneca Plc, H2 2016 22
Pipeline by Carmot Therapeutics Inc, H2 2016 23
Pipeline by Diabetica Limited, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Longevity Biotech, Inc, H2 2016 26
Pipeline by Sanofi, H2 2016 27
Pipeline by Zealand Pharma A/S, H2 2016 28
Dormant Projects, H2 2016 42
Discontinued Products, H2 2016 43

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • 2017-2022 Biomedical Nanotechnology Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
    Published: 29-Mar-2017        Price: US 2960 Onwards        Pages: 126
    This report studies the Biomedical Nanotechnology market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Biomedical Nanotechnology market by product type and applications/end industries. The global Biomedical Nanotechnology market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, gro......
  • Downstream Processing Market by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract Manufacturing Organization) - Global Forecast to 2021
    Published: 29-Mar-2017        Price: US 5650 Onwards        Pages: 139
    The global downstream processing market is projected to reach USD 22.03 billion by 2021 from USD 10.32 billion in 2016, at a CAGR of 16.4% from 2016 to 2021.Increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry are the major factors driving the growth of the global downstream processing market. Developing markets in Asia-Pacific such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore are lucrative markets for d......
  • 2017-2022 China Human Micobiome Market Report (Status and Outlook)
    Published: 27-Mar-2017        Price: US 3360 Onwards        Pages: 113
    The Human Micobiome market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics - Second Genome - Rebiotix - ActoGeniX - Enterome BioScience - AvidBiotics - 4D P......
  • 2017-2022 Global Top Countries Human Micobiome Market Report
    Published: 24-Mar-2017        Price: US 4960 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Human Micobiome in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Vedanta - Seres Therapeutics - Second Genome - Rebiotix - ActoG......
  • 2017-2022 Japan Human Micobiome Market Report (Status and Outlook)
    Published: 24-Mar-2017        Price: US 3360 Onwards        Pages: 113
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics - Se......
  • 2017-2022 UK Human Micobiome Market Report (Status and Outlook)
    Published: 24-Mar-2017        Price: US 3360 Onwards        Pages: 113
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in UK, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In UK market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics - Second G......
  • 2017-2022 United States Human Micobiome Market Report (Status and Outlook)
    Published: 23-Mar-2017        Price: US 3360 Onwards        Pages: 113
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeu......
  • 2017 Top 5 Human Micobiome Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 23-Mar-2017        Price: US 4960 Onwards        Pages: 124
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Human Micobiome in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Human Micobiome Players in each region, with sales, price, revenue and market share for top 5 manufacturer, covering - Vedanta - Seres Therapeutics - Second Genome - Rebiotix - ActoGeniX......
  • 2017-2022 Germany Human Micobiome Market Report (Status and Outlook)
    Published: 23-Mar-2017        Price: US 3360 Onwards        Pages: 113
    "This report will be delivered in 2-3 business days after the order is placed." The Human Micobiome market size will be XX million (USD) in 2022 in Germany, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Germany market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Vedanta - Seres Therapeutics ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs